Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instituto Rosenbusch's Other Operating Expense for the
three
months ended in Dec. 2025 was ARS450 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was ARS1,440 Mil.
Instituto Rosenbusch's quarterly Other Operating Expense
increased
from Jun. 2025 (ARS172 Mil) to Sep. 2025 (ARS549 Mil) but then
declined
from Sep. 2025 (ARS549 Mil) to Dec. 2025 (ARS450 Mil).
Instituto Rosenbusch's annual Other Operating Expense
increased
from Dec. 2023 (ARS1,344 Mil) to Dec. 2024 (ARS1,577 Mil) but then
declined
from Dec. 2024 (ARS1,577 Mil) to Dec. 2025 (ARS1,440 Mil).
Instituto Rosenbusch Other Operating Expense Related Terms
Instituto Rosenbusch Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS1,440 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of ARS1,440 Mil mean?
Instituto Rosenbusch (BUE:ROSE) has a Other Operating Expense of ARS1,440 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Other Operating Expense too high?
Instituto Rosenbusch's current Other Operating Expense is ARS1,440 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Other Operating Expense compare to ZTS and UTHR?
Instituto Rosenbusch's Other Operating Expense of ARS1,440 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Other Operating Expense is ARS1,440 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.77, compared to a current price of ARS162.00 — trading 158.1% above its estimated fair value. The current Other Operating Expense is ARS1,440 Mil. Instituto Rosenbusch's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Other Operating Expense is ARS1,440 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS162.00 is trading 158.1% above its estimated GF Value™ of ARS62.77.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Other Operating Expense: ARS1,440 Mil
GF Value™: ARS62.77 vs. price of ARS162.00 (158.1% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
42GF Score
Get the complete analysis for BUE:ROSE
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
